Workflow
Wabash Announces Second Quarter 2025 Results
Globenewswire· 2025-07-25 10:53
Core Insights - Wabash reported a net sales of $458.8 million for Q2 2025, a decrease of 16.7% compared to Q2 2024 [2][7] - The company experienced a GAAP operating loss of $4.8 million, primarily due to a $5 million loss related to a legal verdict [2][7] - Total backlog as of June 30, 2025, was approximately $1.0 billion, indicating a cautious approach from customers regarding capital spending [3][7] Financial Performance - Consolidated gross profit for Q2 2025 was $41.4 million, representing 9.0% of sales, down from 16.2% in Q2 2024 [2][8] - Non-GAAP adjusted operating loss for the quarter was $0.1 million, while GAAP diluted earnings per share were $(0.23) [2][7] - The company reduced its full-year revenue outlook to approximately $1.6 billion and adjusted EPS guidance to a range of $(1.30) to $(1.00) [3][4] Market Environment - Demand in the trailer industry remains muted, with industry forecasts suggesting that 2025 shipment volumes will fall below basic replacement demand [4][7] - The company is cautiously optimistic about a return to growth in 2026 based on early discussions with customers and current industry forecasts [4][7] Business Segment Highlights - In Q2 2025, new trailers shipped totaled 8,640, down from 9,245 in Q2 2024, while new truck bodies shipped were 3,190, down from 3,925 [6][28] - Transportation Solutions segment net sales were $400.2 million, a decrease of 19.7% year-over-year, with an operating loss of $12.5 million [8][29] - Parts & Services segment net sales increased by 8.8% year-over-year to $59.7 million, with an operating income of $9.1 million [9][29]
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
Globenewswire· 2025-07-25 10:47
Core Viewpoint - Novo Nordisk announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending an update to the Alhemo (concizumab) label to include treatment for severe haemophilia A and moderate or severe haemophilia B without inhibitors [1][4]. Group 1: Product Information - Alhemo (concizumab) is an anti-tissue factor pathway inhibitor designed to block a protein that prevents blood clotting, thus promoting thrombin production to help clot blood and prevent bleeding [5]. - Currently, Alhemo is approved in multiple countries, including Europe, the United States, India, Brazil, and Switzerland, for patients with haemophilia A and B with inhibitors, and in Japan and Australia for both with and without inhibitors [5]. - The product is administered via a user-friendly, pre-filled, portable pen, which is expected to enhance patient adherence and treatment flexibility [2][7]. Group 2: Clinical Trial Results - The positive CHMP opinion is based on the phase 3 explorer8 trial, which demonstrated that Alhemo prophylaxis resulted in an 86% reduction in treated spontaneous bleeds and a 79% reduction in traumatic bleeds for patients with haemophilia A and B without inhibitors, respectively [2][7]. - Patient-Reported Outcome (PRO) data indicated improvements in health-related quality of life and a reduction in treatment burden, with 70.9% of respondents preferring Alhemo over previous treatments [3][6]. Group 3: Regulatory Outlook - Following the positive opinion from the CHMP, Novo Nordisk anticipates that the European Commission will approve the label update within approximately two months [4][7]. - If approved, Alhemo will be available to all adult and pediatric patients aged 12 years and older living with severe haemophilia A and moderate or severe haemophilia B without inhibitors [7].
AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call
Globenewswire· 2025-07-25 10:45
Company Overview - AirSculpt Technologies, Inc. is an industry leader in premium body contouring procedures, focusing on next-generation treatments that optimize comfort and precision [3]. Financial Results Announcement - AirSculpt will report its second quarter 2025 financial results before the market opens on August 1, 2025, followed by a conference call at 8:30 a.m. Eastern Time on the same day [1]. Conference Call Details - The conference call can be accessed via a toll-free domestic number (1-877-407-9716) or an international number (1-201-493-6779) using the conference ID 13754561, with a live webcast available on the investor relations section of the AirSculpt website [2].
W&T Offshore Announces Timing of Second Quarter 2025 Earnings Release and Conference Call
Globenewswire· 2025-07-25 10:45
Core Viewpoint - W&T Offshore, Inc. is set to release its second quarter 2025 earnings on August 4, 2025, followed by a conference call on August 5, 2025, to discuss financial and operational results [1] Company Overview - W&T Offshore, Inc. is an independent oil and natural gas producer operating in the Gulf of America, with growth achieved through acquisitions, exploration, and development [2] - As of March 31, 2025, the company holds working interests in 52 fields, including 45 in federal waters and 7 in state waters [2] - The company has approximately 634,700 gross acres (496,900 net acres) under lease, with 487,200 gross acres on the conventional shelf, 141,900 gross acres in deepwater, and 5,600 gross acres in Alabama state waters [2] - A majority of the company's daily production comes from wells it operates [2]
First Citizens BancShares Reports Second Quarter 2025 Earnings, Announces Additional Share Repurchase Plan
Prnewswire· 2025-07-25 10:32
RALEIGH, N.C., July 25, 2025 /PRNewswire/ -- First Citizens BancShares, Inc. ("BancShares") (Nasdaq: FCNCA) reported earnings for the second quarter of 2025. Chairman and CEO Frank B. Holding, Jr. said: "Our team delivered solid financial results in the second quarter through revenue growth and positive credit performance across our diverse portfolio. Capital and liquidity positions remained strong, enabling us to return an additional $613 million of capital to our stockholders through share repurchases dur ...
Inception Growth Acquisition Limited Announces Adjournment of the Special Meeting to August 8, 2025
Globenewswire· 2025-07-25 10:15
New York, July 25, 2025 (GLOBE NEWSWIRE) -- Inception Growth Acquisition Limited (the “Company”), a blank check company, today announced that it convened its special meeting (“Special Meeting”) and immediately adjourned the Special Meeting, without conducting any business, to August 8, 2025. The Special Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on May 27, 2025, as supplemented by the supple ...
Ambow Launches HybriU Global Learning Network, Connecting U.S. Universities with Students Worldwide
Globenewswire· 2025-07-25 10:00
New Phygital Infrastructure Empowers U.S. Universities to Expand Globally Through AI-powered Hybrid Classrooms CUPERTINO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Ambow Education Holding Ltd. (NYSE American: AMBO), a U.S.-based innovator of AI-powered phygital (physical + digital) solutions for education, corporate collaboration and live events, today announced the launch of its HybriU Global Learning Network (HGLN), a two-pronged initiative designed to help U.S. universities scale international enrollme ...
RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call
Globenewswire· 2025-07-25 10:00
LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2025 financial results on Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet’s conference call by dia ...
XPENG Launches Global Localization Strategy in Indonesia with First Locally-produced X9 Delivery
Globenewswire· 2025-07-25 09:59
Core Insights - XPENG Motors has commenced localized production in Indonesia, marking a significant milestone in its global manufacturing strategy [2][3][5] - The first locally produced XPENG X9 was delivered at the 2025 Gaikindo Indonesia International Auto Show (GIIAS), showcasing the company's commitment to local market needs [2][6][10] - The New G6 was also unveiled at GIIAS, highlighting XPENG's accelerated global expansion and technological advancements [2][11] Localization and Production - Indonesia is the first country where XPENG has localized its vehicle production, with the Purwakarta factory rolling out the first X9 [3][4] - The establishment of local production enhances XPENG's responsiveness to Southeast Asian market demands and accelerates the adoption of advanced technologies [5][10] - The XPENG X9 features a spaceship-inspired design and has already gained popularity, with 30,000 families worldwide expressing interest [8][10] Technological Advancements - The XPENG New G6, unveiled at GIIAS, is powered by advanced technology including the Qualcomm Snapdragon 8295 chipset and NVIDIA Orin-X processor, offering superior AI processing and graphics capabilities [11] - The X9 is equipped with a smart cockpit and advanced driving systems, aligning with the needs of Indonesian families [10][11] Strategic Importance - Indonesia is recognized as Southeast Asia's largest automotive market, making it strategically significant for XPENG's expansion plans [5][10] - The company's investment in local production reflects its commitment to bringing advanced technologies to Indonesia and fostering sustainable growth [13]
Southside Bancshares, Inc. Announces Financial Results for the Second Quarter Ended June 30, 2025
Globenewswire· 2025-07-25 09:45
Core Viewpoint - Southside Bancshares, Inc. reported a decrease in net income and earnings per share for the second quarter of 2025 compared to the same period in 2024, primarily due to increased noninterest expenses and provisions for credit losses, despite growth in net interest income and noninterest income [1][3][10]. Financial Performance - Net income for the three months ended June 30, 2025, was $21.8 million, down from $24.7 million in 2024, a decrease of 11.6% [1][3]. - Earnings per diluted common share decreased to $0.72 from $0.81, a decline of 11.1% [1][3]. - Annualized return on average shareholders' equity was 10.73%, down from 12.46% in the same period last year [1][3]. - Annualized return on average assets was 1.07%, compared to 1.19% in 2024 [1][3]. Income and Expenses - Net interest income increased to $54.3 million, a rise of 1.2% from $53.9 million in the previous quarter [4][6]. - Noninterest income rose to $12.1 million, up 5.1% from $11.6 million in 2024 [6][11]. - Noninterest expenses increased by 9.8% to $39.3 million, primarily due to higher professional fees and salaries [8][14]. Asset Quality - Nonperforming assets increased to $32.9 million, or 0.39% of total assets, compared to $6.9 million, or 0.08% of total assets, in 2024 [23][24]. - The allowance for loan losses was $44.4 million, or 0.97% of total loans, slightly up from 0.92% in the previous year [24]. Balance Sheet Highlights - Total assets as of June 30, 2025, were $8.34 billion, a decrease from $8.52 billion at the end of 2024 [16][38]. - Total loans were $4.60 billion, a slight increase of 0.3% from $4.59 billion in 2024 [16][17]. - Total deposits increased to $6.63 billion, up 2.1% from $6.50 billion in 2024 [18][19]. Capital and Liquidity - The company had $2.33 billion in total available contingent liquidity as of June 30, 2025 [22][21]. - The company repurchased 424,435 shares of common stock at an average price of $28.13 per share during the second quarter [21].